Drive incremental sales with iROAS — an industry-leading metric
We are committed to providing our partners* with transparent measurement solutions, which is why we have recently enhanced our offering to include a new, industry-leading iROAS measurement methodology.
CMX™ provides partners a robust incrementality model designed to:
- Measure the true impact of ad spend
- Refine media strategies
- Drive sales based on actual observed outcomes — not predicted behaviors
Providing partners with incrementality understanding is a top priority for CMX, too
71% of advertisers recognize incrementality as the most important KPI in RMN investments* according to the ANA, underscoring the growing importance of this approach.
The impact of a balanced test-and-control methodology
Partners gain high accuracy, clear causality and experimental control, ensuring that results reflect the true effectiveness of their marketing efforts. In accordance with IAB standards, CMX uses balanced test vs. control groups, removing bias inherent in other RMN methods.
How we approach iROAS at CMX
-
Audience randomization
CMX randomizes and sorts individuals into test and control groups to ensure the groups are identical, balanced and unbiased.
-
Performance measurement
We only use viewable impressions to measure performance, with highly deterministic sales based on real people and real purchases to understand lift.
-
Incremental sales evaluation
Incremental sales are evaluated as a combination of the observed sales difference for current brand buyers and total spend for new to brand buyers.
We’re the 1st health & wellness RMN to align with leading IAB standards
With our best-in-class measurement methodology, we can efficiently evaluate how qualifying campaigns drive incremental sales.*
Contact your partner manager today to learn more about our iROAS
measurement capabilities.
*Inquire about minimum investment and campaign parameters.